In previous publications the role of kininogen system has been postulated. On those publications the possible role of Icatibant, Ecallantide and Aprotinin in treatment of SARS Cov-2 has been raised. In this paper we raise the hypothetical potential of Methylene Blue in treatment of SARS COV 2. This medication may abort effects of Bradykinin by inhibition of NO Synthase inhibitor and promote oxygen saturation while it is inexpensive and ubiquitously accessible. Clinical studies can not be over emphasized.